Pembrolizumab Activity in BCG-Refractory Papillary Bladder Cancer

Pembrolizumab monotherapy showed promising antitumor activity for patients with high-risk non–muscle invasive bladder cancer that did not respond to standard treatment with BCG.

Related Keywords

Italy ,Boston ,Massachusetts ,United States ,Netherlands ,Dana Farber Cancer Institute ,Amsterdam ,Noord Holland ,American ,Andrea Necchi ,Michiel Simon ,Bradley Alexander Mcgregor ,Lank Center ,Scientific Institute ,Salute San Raffaele University ,American Society Of Clinical Oncology ,Netherlands Cancer Institute ,Vita Salute San Raffaele University ,Raffaele Hospital ,Genitourinary Cancers Symposium ,American Society ,Genitourinary Oncology ,Prognosis After Relapse ,Some Concerns ,Bladder Cancer ,Alignant Bladder Neoplasm ,Radical Cystectomy Of The Bladder ,Cancer ,Alignant Neoplasia ,Arcinoma ,Bladder ,Biologic Therapy ,Thyroid Disorder ,Toxicology ,Refractory ,Cystectomy Removal Ofa Cyst ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Clinical Research ,Clinical Trials ,Linical Studies ,Muscles ,Papillary Tumor ,It ,